Elise Schutte1, Hiddo J Lambers Heerspink2, Helen L Lutgers3, Stephan J L Bakker1, Priya Vart4, Bruce H R Wolffenbuttel3, Kausik Umanath5, Julia B Lewis6, Dick de Zeeuw2, Ron T Gansevoort7. 1. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 2. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 3. Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 4. Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 5. Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI. 6. Division of Nephrology, Vanderbilt University, Nashville, TN. 7. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: r.t.gansevoort@umcg.nl.
Abstract
BACKGROUND: Low serum bicarbonate level has been reported to be an independent predictor of kidney function decline and mortality in patients with chronic kidney disease. Mechanisms underlying low serum bicarbonate levels may differ in patients with and without diabetes. We aimed to specifically investigate the association of serum bicarbonate level with kidney disease progression and cardiovascular outcome in a cohort of patients with type 2 diabetes and nephropathy. STUDY DESIGN: Post hoc analysis of 2 multicenter randomized controlled trials. SETTING & PARTICIPANTS: 2,628 adults with type 2 diabetes and nephropathy. FACTOR: Serum bicarbonate level. OUTCOMES: Incidence of: (1) end-stage renal disease (ESRD), (2) ESRD or doubling of serum creatinine level, (3) all-cause mortality, (4) cardiovascular events (fatal/nonfatal stroke/myocardial infarction), and (5) heart failure. MEASUREMENTS: Serum bicarbonate was measured at baseline as total carbon dioxide. Associations of baseline serum bicarbonate level with end points were investigated using Cox regression models. Serum bicarbonate levels were studied as a continuous variable and stratified in quartiles. Follow-up was 2.8±1.0 (SD) years. RESULTS: Cox regression analyses showed that serum bicarbonate level had inverse associations with incident ESRD (HR, 0.91; 95% CI, 0.89-0.93; P<0.001) and incidence of the combined end point of ESRD or serum creatinine doubling (HR, 0.94; 95% CI, 0.92-0.96; P<0.001). These associations were independent of age, sex, and cardiovascular risk factors, but disappeared after adjustment for baseline estimated glomerular filtration rate (all P>0.05). Analysis of bicarbonate quartiles showed similar results for the quartile with the lowest bicarbonate (≤21 mEq/L) versus the quartile with normal bicarbonate levels (24-26 mEq/L). There was no association of bicarbonate level with cardiovascular events and heart failure. LIMITATIONS: Post hoc analysis and single measurement of serum bicarbonate. CONCLUSIONS: In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations.
RCT Entities:
BACKGROUND: Low serum bicarbonate level has been reported to be an independent predictor of kidney function decline and mortality in patients with chronic kidney disease. Mechanisms underlying low serum bicarbonate levels may differ in patients with and without diabetes. We aimed to specifically investigate the association of serum bicarbonate level with kidney disease progression and cardiovascular outcome in a cohort of patients with type 2 diabetes and nephropathy. STUDY DESIGN: Post hoc analysis of 2 multicenter randomized controlled trials. SETTING & PARTICIPANTS: 2,628 adults with type 2 diabetes and nephropathy. FACTOR: Serum bicarbonate level. OUTCOMES: Incidence of: (1) end-stage renal disease (ESRD), (2) ESRD or doubling of serum creatinine level, (3) all-cause mortality, (4) cardiovascular events (fatal/nonfatal stroke/myocardial infarction), and (5) heart failure. MEASUREMENTS: Serum bicarbonate was measured at baseline as total carbon dioxide. Associations of baseline serum bicarbonate level with end points were investigated using Cox regression models. Serum bicarbonate levels were studied as a continuous variable and stratified in quartiles. Follow-up was 2.8±1.0 (SD) years. RESULTS: Cox regression analyses showed that serum bicarbonate level had inverse associations with incident ESRD (HR, 0.91; 95% CI, 0.89-0.93; P<0.001) and incidence of the combined end point of ESRD or serum creatinine doubling (HR, 0.94; 95% CI, 0.92-0.96; P<0.001). These associations were independent of age, sex, and cardiovascular risk factors, but disappeared after adjustment for baseline estimated glomerular filtration rate (all P>0.05). Analysis of bicarbonate quartiles showed similar results for the quartile with the lowest bicarbonate (≤21 mEq/L) versus the quartile with normal bicarbonate levels (24-26 mEq/L). There was no association of bicarbonate level with cardiovascular events and heart failure. LIMITATIONS: Post hoc analysis and single measurement of serum bicarbonate. CONCLUSIONS: In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations.
Authors: Mirela Dobre; Jason Roy; Kaixiang Tao; Amanda H Anderson; Nisha Bansal; Jing Chen; Rajat Deo; Paul Drawz; Harold I Feldman; L Lee Hamm; Thomas Hostetter; John W Kusek; Claudia Lora; Akinlolu O Ojo; Kumar Shrama; Mahboob Rahman Journal: Am J Nephrol Date: 2016-05-28 Impact factor: 3.754
Authors: Miles D Witham; Margaret Band; Huey Chong; Peter T Donnan; Geeta Hampson; May Khei Hu; Roberta Littleford; Edmund Lamb; Philip A Kalra; Gwen Kennedy; Paul McNamee; Deirdre Plews; Petra Rauchhaus; Roy L Soiza; Deepa Sumukadas; Graham Warwick; Alison Avenell Journal: Health Technol Assess Date: 2020-06 Impact factor: 4.014
Authors: Julia J Scialla; John Asplin; Mirela Dobre; Alex R Chang; James Lash; Chi-Yuan Hsu; Radhakrishna R Kallem; L Lee Hamm; Harold I Feldman; Jing Chen; Lawrence J Appel; Cheryl A M Anderson; Myles Wolf Journal: Kidney Int Date: 2016-12-01 Impact factor: 10.612
Authors: Jessica B Kendrick; Leila Zelnick; Michel B Chonchol; David Siscovick; Andrew N Hoofnagle; Joachim H Ix; Mark Sarnak; Michael G Shlipak; Bryan Kestenbaum; Ian H de Boer Journal: Am J Nephrol Date: 2016-12-10 Impact factor: 3.754
Authors: Mirela Dobre; Nicholas M Pajewski; Srinivasan Beddhu; Michel Chonchol; Thomas H Hostetter; Ping Li; Mahboob Rahman; Karen Servilla; Daniel E Weiner; Jackson T Wright; Kalani L Raphael Journal: Nephrol Dial Transplant Date: 2020-08-01 Impact factor: 5.992
Authors: Navdeep Tangri; Nancy L Reaven; Susan E Funk; Thomas W Ferguson; David Collister; Vandana Mathur Journal: BMC Nephrol Date: 2021-05-19 Impact factor: 2.388